Jubiglim MV 2 Plus Tablet SR is a combination oral antidiabetic medication formulated to improve glycemic control in patients with type 2 diabetes mellitus. It contains Glimepiride (2 mg), Metformin (500 mg), and Voglibose (0.3 mg), each contributing distinct mechanisms to regulate blood glucose levels. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose concentrations. Metformin, a biguanide, primarily decreases hepatic glucose production and enhances peripheral insulin sensitivity, promoting glucose uptake by muscle tissues. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption in the intestines, leading to a reduction in postprandial hyperglycemia. The sustained-release formulation ensures a gradual release of active ingredients, improving patient compliance and minimizing gastrointestinal side effects commonly associated with metformin. Jubiglim MV 2 Plus is indicated for patients inadequately controlled by diet and exercise alone or those requiring combination therapy to achieve target glycemic levels. It should be used under medical supervision with regular monitoring of blood glucose and renal function. Caution is advised in patients with hepatic impairment, renal dysfunction, or a history of lactic acidosis. This combination therapy offers a comprehensive approach to managing type 2 diabetes by targeting multiple pathophysiological defects.